Development and Validation of the GLORI-COPD Score

University of Paris 5 - Rene Descartes462 enrolled

Overview

The objective of this study is to evaluate the diagnostic accuracy of the GLORI-COPD score in ambulatory care, to enable the screening of COPD patients at risk of complications, requiring early management

Chronic obstructive pulmonary disease (COPD) is a chronic disease with a high prevalence in France, but which remains under-diagnosed due to the trivialization of symptoms and difficulty in accessing diagnostic investigations. It is associated with other co-morbidities, with an impact on the occurrence of complications and quality of life. Early management of the most severe patients would allow better control of these risks of complications. Our objective is to better identify patients with COPD at risk of complications in general practice, taking into account the totality of the patient, to improve their management.

Study Type

OBSERVATIONAL

Enrollment

462

Conditions

Pulmonary Disease, Chronic Obstructive

Eligibility

Sex: ALLMin age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age ≥ 35 yo * smoker or former smoker ≥ 10 Pack Years Exclusion Criteria: * Patients who have already been diagnosed with COPD by spirometry, * have a contraindication to spirometry, * have an estimated life expectancy of less than 5 years * are under protective measures

Locations (1)

Université Paris Cité

Paris, France

Outcomes

Primary Outcomes

diagnostic accuracy of the score

The diagnostic accuracy of the score will be evaluated to determine the risk of pulmonary complication in patients with COPD. Sensitivity, specificity, positive predictive value and negative predictive value

Time frame: 12 months

Secondary Outcomes

COPD diagnosis

FEV1/FVC \< 0.7

Time frame: Baseline

complications

-Composite criterion: Occurrence of a low respiratory infection (bronchitis, COPD exacerbation, lung infection or pneumonitis) in an outpatient or inpatient setting or following a death (1st event)

Time frame: 6 and 12 months

death

Time frame: 12 months

Modified Medical Research Council Dyspnea scale score (mMRC)

evaluating dyspnea from 0 to 4: 0, no breathlessness except on strenuous exercise; 1, shortness of breath when hurrying on the level or walking up a slight hill; 2, walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level; 3, stops for breath after walking ∼100 m or after few minutes on the level; and 4, too breathless to leave the house, or breathless when dressing or undressing

Time frame: baseline, 6 and 12 months

COPD Assessment test (CAT)

scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life

Time frame: baseline, 6 and 12 months

ADO index (Age, Dyspnea, Obstruction)

evaluates mortality risk in copd patients from 0 to 14 (higher scores are linked woh higher mortality risk)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.